--- title: "JAN (NYSE:JAN) Lowered to \"Hold\" Rating by Zacks Research" type: "News" locale: "en" url: "https://longbridge.com/en/news/295790408.md" description: "Zacks Research downgraded JAN (Janus Living) from 'strong-buy' to 'hold'. Other analysts like Barclays and JPMorgan maintain positive ratings with price targets between $26-$34. Despite a recent quarterly EPS miss, revenue grew 45.4% YoY. The company recently priced a public offering of 16 million shares at $29, causing dilution pressure and contributing to a 1.2% stock decline." datetime: "2026-08-13T11:30:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295790408.md) - [en](https://longbridge.com/en/news/295790408.md) - [zh-HK](https://longbridge.com/zh-HK/news/295790408.md) generator: "portal-rs" --- # JAN (NYSE:JAN) Lowered to "Hold" Rating by Zacks Research JAN (NYSE:JAN - Get Free Report) was downgraded by stock analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Other equities analysts also recently issued research reports about the company. Barclays upped their target price on JAN from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Tuesday, July 7th. Weiss Ratings started coverage on shares of JAN in a research note on Thursday, August 6th. They issued a "hold (c-)" rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of JAN in a report on Tuesday, April 14th. They set an "overweight" rating and a $26.00 price target on the stock. UBS Group set a $29.00 price objective on shares of JAN in a research report on Thursday, June 18th. Finally, BNP Paribas Exane initiated coverage on shares of JAN in a research note on Tuesday, April 14th. They issued an "outperform" rating and a $27.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, JAN presently has an average rating of "Moderate Buy" and a consensus target price of $30.15. **Read Our Latest Report on JAN** ## JAN Stock Down 1.2% Shares of JAN stock opened at $29.21 on Tuesday. JAN has a 52 week low of $22.76 and a 52 week high of $32.83. The company has a market cap of $7.69 billion and a P/E ratio of -584.20. The business's 50-day moving average is $28.62. JAN (NYSE:JAN - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.18). The business had revenue of $216.46 million for the quarter, compared to analysts' expectations of $203.32 million. The company's revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. As a group, equities research analysts anticipate that JAN will post 0.97 earnings per share for the current fiscal year. ## JAN News Roundup Here are the key news stories impacting JAN this week: - Positive Sentiment: An analyst upgrade triggered unusually high trading volume, indicating increased investor interest in JAN and helping support the shares. The specific rating change was not disclosed in the available report. JAN Sees Unusually-High Trading Volume on Analyst Upgrade - Positive Sentiment: Royal Bank of Canada raised its price target to **$34**, above the stock’s recent trading level, reinforcing the view that Janus Living’s senior-housing portfolio and growth strategy may offer further upside. Royal Bank of Canada Boosts JAN Price Target to $34 - Positive Sentiment: Janus Living’s latest quarter showed strong demand, with revenue rising 45.4% year over year to $216.5 million and full-year 2026 EPS guidance set at $0.95-$0.98. Institutional ownership activity was also broadly supportive, with 120 investors adding shares versus four reducing positions in the latest reported period. - Neutral Sentiment: The company’s quarterly EPS of $0.05 missed the $0.23 consensus estimate despite revenue exceeding expectations. This creates some concern about profitability, although management maintained its full-year outlook. - Negative Sentiment: Janus Living priced a public offering of 16 million Class A-1 shares at $29 per share, with an option for underwriters to purchase up to 2.4 million additional shares. The added share supply is creating dilution pressure and appears to be outweighing the company’s operating momentum in the near term. Proceeds will fund acquisitions, investments and general corporate purposes. Why Janus Living Stock Is Down Today ## JAN Company Profile (Get Free Report) Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025. ## Read More - Five stocks we like better than JAN - GE Vernova’s AI Power Boom Faces a Profit Test - Cardinal Health Earnings: Can Perfection Get Priced In Twice? - Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand - Legacy Jet Builders Stall While Embraer Accelerates to New Highs *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in JAN Right Now? Before you consider JAN, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and JAN wasn't on the list. While JAN currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [JAN.US](https://longbridge.com/en/quote/JAN.US.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [GEV.US](https://longbridge.com/en/quote/GEV.US.md) - [CAH.US](https://longbridge.com/en/quote/CAH.US.md) - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [ERJ.US](https://longbridge.com/en/quote/ERJ.US.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [EMBJ.US](https://longbridge.com/en/quote/EMBJ.US.md) ## Related News & Research - [Assessing Janus Living (JAN) Valuation As Senior Housing REIT Draws Fresh Investor Attention](https://longbridge.com/en/news/287991471.md) - [Janus Living Announces Pricing of Public Offering of Class A-1 Common Stock | JAN Stock News](https://longbridge.com/en/news/295466047.md) - [Alliance Laundry COO-International Jan Gommaar M. Vleugels disposes of USD 1.86 million in common shares](https://longbridge.com/en/news/296361448.md) - [Goldman's top economist says the Fed's opaque new communication style will stir up market 'cacophony'](https://longbridge.com/en/news/296598952.md) - [Zacks Research Comments on Autoliv's Q4 Earnings (NYSE:ALV)](https://longbridge.com/en/news/296222872.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**